Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 6, 2012, Pages 631-639

  Mizuno, Tomoyuki ^a   Fukudo, Masahide ^a   Terada, Tomohiro ^a,c   Kamba, Tomomi ^b   Nakamura, Eijiro ^b   Ogawa, Osamu ^b   Inui, Ken Ichi ^a,d   Katsura, Toshiya ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ABCB1; ABCG2; Pharmacogenetics; Pharmacogenomics; Transporter; Tyrosine kinase inhibitor

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; N DEETHYLSUNITINIB; SUNITINIB; UNCLASSIFIED DRUG;

ACNE; ADULT; AGED; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FATIGUE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAND FOOT SYNDROME; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; WILD TYPE;

EID: 84871692639     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-026     Document Type: Article

References (42)

1. Chow, L. Q. and Eckhardt, S. G.: Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol., 25: 884-896 (2007).
2. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M. and Figlin, R. A.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 356: 115-124 (2007).
3. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., Garcia-del-Muro, X., Sosman, J. A., Solska, E., Wilding, G., Thompson, J. A., Kim, S. T., Chen, I., Huang, X. and Figlin, R. A.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 27: 3584-3590 (2009).
4. Uemura, H., Shinohara, N., Yuasa, T., Tomita, Y., Fujimoto, H., Niwakawa, M., Mugiya, S., Miki, T., Nonomura, N., Takahashi, M., Hasegawa, Y., Agata, N., Houk, B., Naito, S. and Akaza, H.: A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: Insights into the treatment, efficacy and safety. Jpn. J. Clin. Oncol., 40: 194-202 (2010).
5. Hong, M. H., Kim, H. S., Kim, C., Ahn, J. R., Chon, H. J., Shin, S. J., Ahn, J. B., Chung, H. C. and Rha, S. Y.: Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res. Treat., 41: 67-72 (2009).
6. Yoo, C., Kim, J. E., Lee, J. L., Ahn, J. H., Lee, D. H., Lee, J. S., Na, S., Kim, C. S., Hong, J. H., Hong, B., Song, C. and Ahn, H.: The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn. J. Clin. Oncol., 40: 980-985 (2010).
7. Noguchi, K., Katayama, K., Mitsuhashi, J. and Sugimoto, Y.: Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev., 61: 26-33 (2009).
8. Hegedus, T., Orfi, L., Seprodi, A., Varadi, A., Sarkadi, B. and Keri, G.: Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta, 1587: 318-325 (2002).
9. Vlaming, M. L., Lagas, J. S. and Schinkel, A. H.: Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev., 61: 14-25 (2009).
10. Lin, J. H. and Yamazaki, M.: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet., 42: 59-98 (2003).
11. Cascorbi, I.: Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther., 112: 457-473 (2006).
12. Sparreboom, A., Danesi, R., Ando, Y., Chan, J. and Figg, W. D.: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat., 6: 71-84 (2003).
13. Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y. and Sugimoto, Y.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther., 1: 611-616 (2002).
14. Sparreboom, A., Gelderblom, H., Marsh, S., Ahluwalia, R., Obach, R., Principe, P., Twelves, C., Verweij, J. and McLeod, H. L.: Diflomotecan pharmacokinetics in relation to ABCG2 421ChA genotype. Clin. Pharmacol. Ther., 76: 38-44 (2004).
15. Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., Ando, Y., Irie, S., Ware, J., Nakai, Y., Higuchi, S. and Sugiyama, Y.: Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin. Pharmacol. Ther., 84: 95-103 (2008).
16. Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H. and Schellens, J. H.: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res., 65: 2577-2582 (2005).
17. Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L. and Ware, J. A.: Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm., 3: 55-61 (2006).
18. Marchetti, S., de Vries, N. A., Buckle, T., Bolijn, M. J., van Eijndhoven, M. A., Beijnen, J. H., Mazzanti, R., van Tellingen, O. and Schellens, J. H.: Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1%/%/Mdr1a/1b%/% (triple-knockout) and wild-type mice. Mol. Cancer Ther., 7: 2280-2287 (2008).
19. Mizuno, T., Terada, T., Kamba, T., Fukudo, M., Katsura, T., Nakamura, E., Ogawa, O. and Inui, K.: ABCG2 421ChA polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann. Oncol., 21: 1382-1383 (2010).
20. Hu, S., Chen, Z., Franke, R., Orwick, S., Zhao, M., Rudek, M. A., Sparreboom, A. and Baker, S. D.: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin. Cancer Res., 15: 6062-6069 (2009).
21. Onoue, M., Terada, T., Kobayashi, M., Katsura, T., Matsumoto, S., Yanagihara, K., Nishimura, T., Kanai, M., Teramukai, S., Shimizu, A., Fukushima, M. and Inui, K.: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol., 14: 136-142 (2009).
22. Cascorbi, I., Gerloff, T., Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M., Schaeffeler, E., Eichelbaum, M., Brinkmann, U. and Roots, I.: Frequency of single nucleotide polymorphisms in the Pglycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther., 69: 169-174 (2001).
23. Goto, M., Masuda, S., Saito, H., Uemoto, S., Kiuchi, T., Tanaka, K. and Inui, K.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics, 12: 451-457 (2002).
24. Aghazadeh-Habashi, A., Sattari, S., Pasutto, F. and Jamali, F.: Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J. Pharm. Pharm. Sci., 5: 181-184 (2002).
25. O'Farrell, A. M., Foran, J. M., Fiedler, W., Serve, H., Paquette, R. L., Cooper, M. A., Yuen, H. A., Louie, S. G., Kim, H., Nicholas, S., Heinrich, M. C., Berdel, W. E., Bello, C., Jacobs, M., Scigalla, P., Manning, W. C., Kelsey, S. and Cherrington, J. M.: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res., 9: 5465-5476 (2003).
26. Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., Chidambaram, N., Jiang, J. X., Tang, S., Mahjoob, K., Justice, R. and Pazdur, R.: Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res., 13: 1367-1373 (2007).
27. Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Hariharan, S., Lee, S. H., Haanen, J., Castellano, D., Vrdoljak, E., Schoffski, P., Mainwaring, P., Nieto, A., Yuan, J. and Bukowski, R.: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol., 10: 757-763 (2009).
28. Houk, B. E., Bello, C. L., Kang, D. and Amantea, M.: A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res., 15: 2497-2506 (2009).
29. de Jong, F. A., Marsh, S., Mathijssen, R. H., King, C., Verweij, J., Sparreboom, A. and McLeod, H. L.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res., 10: 5889-5894 (2004).
30. Tang, S. C., Lagas, J. S., Lankheet, N. A., Poller, B., Hillebrand, M. J., Rosing, H., Beijnen, J. H. and Schinkel, A. H.: Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int. J. Cancer, 130: 223-233 (2012).
31. Poonkuzhali, B., Lamba, J., Strom, S., Sparreboom, A., Thummel, K., Watkins, P. and Schuetz, E.: Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab. Dispos., 36: 780-795 (2008).
32. van Erp, N. P., Eechoute, K., van der Veldt, A. A., Haanen, J. B., Reyners, A. K., Mathijssen, R. H., Boven, E., van der Straaten, T., Baak-Pablo, R. F., Wessels, J. A., Guchelaar, H. J. and Gelderblom, H.: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol., 27: 4406-4412 (2009).
33. van der Veldt, A. A., Eechoute, K., Gelderblom, H., Gietema, J., Guchelaar, H. J., van Erp, N. P., van den Eertwegh, A. J., Haanen, J. B., Mathijssen, R. H. and Wessels, J. A.: Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res., 17: 620-629 (2011).
34. Garcia-Donas, J., Esteban, E., Leandro-Garcia, L. J., Castellano, D. E., del Alba, A. G., Climent, M. A., Arranz, J. A., Gallardo, E., Puente, J., Bellmunt, J., Mellado, B., Martinez, E., Moreno, F., Font, A., Robledo, M. and Rodriguez-Antona, C.: Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol., 12: 1143-1150 (2011).
35. Macphee, I. A., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L. and Holt, D. W.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation, 74: 1486-1489 (2002).
36. Anglicheau, D., Verstuyft, C., Laurent-Puig, P., Becquemont, L., Schlageter, M. H., Cassinat, B., Beaune, P., Legendre, C. and Thervet, E.: Association of the multidrug resistance-1 gene singlenucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol., 14: 1889-1896 (2003).
37. Hosohata, K., Masuda, S., Yonezawa, A., Katsura, T., Oike, F., Ogura, Y., Takada, Y., Egawa, H., Uemoto, S. and Inui, K.: MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm. Res., 26: 1590-1595 (2009).
38. Tsuchiya, N., Satoh, S., Tada, H., Li, Z., Ohyama, C., Sato, K., Suzuki, T., Habuchi, T. and Kato, T.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 78: 1182-1187 (2004).
39. Chowbay, B., Li, H., David, M., Cheung, Y. B. and Lee, E. J.: Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br. J. Clin. Pharmacol., 60: 159-171 (2005).
40. Kimchi-Sarfaty, C., Marple, A. H., Shinar, S., Kimchi, A. M., Scavo, D., Roma, M. I., Kim, I. W., Jones, A., Arora, M., Gribar, J., Gurwitz, D. and Gottesman, M. M.: Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics, 8: 29-39 (2007).
41. Britten, C. D., Kabbinavar, F., Hecht, J. R., Bello, C. L., Li, J., Baum, C. and Slamon, D.: A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol., 61: 515-524 (2008).
42. Kodaira, H., Kusuhara, H., Ushiki, J., Fuse, E. and Sugiyama, Y.: Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther., 333: 788-796 (2010).